Compare CAPR & JJSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | JJSF |
|---|---|---|
| Founded | 2005 | 1971 |
| Country | United States | United States |
| Employees | N/A | 1800 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2011 | 1995 |
| Metric | CAPR | JJSF |
|---|---|---|
| Price | $35.29 | $81.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $44.63 | ★ $140.00 |
| AVG Volume (30 Days) | ★ 1.0M | 220.6K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 3.92% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $1,022,038,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | $3.31 | $1.70 |
| P/E Ratio | ★ N/A | $1,631.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $73.75 |
| 52 Week High | $40.37 | $142.69 |
| Indicator | CAPR | JJSF |
|---|---|---|
| Relative Strength Index (RSI) | 65.11 | 51.98 |
| Support Level | $22.09 | $80.23 |
| Resistance Level | $36.49 | $83.03 |
| Average True Range (ATR) | 2.10 | 2.24 |
| MACD | 0.21 | 0.32 |
| Stochastic Oscillator | 79.14 | 73.35 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.